BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37831592)

  • 1. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
    Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
    Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
    Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
    J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
    Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
    Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
    Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
    Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
    Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
    Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1:
    Tritto V; Ferrari L; Esposito S; Zuccotti P; Bianchessi D; Natacci F; Saletti V; Eoli M; Riva P
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31694342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
    Mazuelas H; Carrió M; Serra E
    Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.
    Banerjee J; Allaway RJ; Taroni JN; Baker A; Zhang X; Moon CI; Pratilas CA; Blakeley JO; Guinney J; Hirbe A; Greene CS; Gosline SJ
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
    Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
    Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
    Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
    Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
    Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
    Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
    Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
    Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
    Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
    Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg.
    Friedrich RE; Hagel C; Kohlrusch FK; Schanze I; Wieland I; Zenker M
    Anticancer Res; 2020 Jun; 40(6):3423-3427. PubMed ID: 32487640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.